The UAB Comprehensive Cancer Center and the Center for Clinical & Translational Science proudly present:
Systems BioMedicine Symposium
Thursday, May 9, 2013
8 a.m. to 12:30 p.m.
Edge of Chaos Auditorium, Lister Hill Library
For more information, contact Spira Steyn, 975-0438, email@example.com
This event is free, but registration is required due to limited seating. Click here to register!
Speakers and topics will include:
Eric E. Schadt, Ph.D., Mount Sinai School of Medicine – “From Big Data to Predictive Models of Disease (A Multiscale Biology View)”
Dr. Schadt is the Director of the Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences and the Jean C. and James W. Crystal Professor of Genomics at Mount Sinai School of Medicine. He is an industry leader in network biology with a number of high-profile publications over the past 5 years and is the Editor-in-Chief of the new journal Open Network Biology. Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. His research has provided novel insights into what is needed to master diverse, large-scale data collected on normal and disease populations in order to elucidate the complexity of disease and make more informed decisions in the drug discovery arena.
Stephen H. Friend, M.D., Ph.D., Sage BioNetworks Inc. – “Transitioning to a Data-Driven World Is Not About Why But How”
Dr. Friend is the President, Co-Founder and Director of Sage Bionetworks. He was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. In 2005, he led the Advanced Technologies and Oncology groups to firmly establish molecular profiling activities throughout Merck’s laboratories around the world, as well as to coordinate oncology programs from Basic Research through phase IIA clinical trials. Prior to joining Merck, Dr. Friend along with Dr. Leland Hartwell founded and co-led the Fred Hutchinson Cancer Research Center’s “Seattle Project”, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.
Gordon B. Mills, M.D., Ph.D., MD Anderson Cancer Center – “Systems Approach to Drug Development and Implementation”
Dr. Mills is Chairman of the Department of Systems Biology, Division of Cancer Medicine, Chief of the Section of Molecular Therapeutics, Professor of Medicine and Immunology, Olga Keith Weiss Distinguished University Chair for Cancer Research, and Anne Rife Cox Chair in Gynecology. Dr. Mills’ extensive experience with rapidly evolving technology used in the discovery of biomarkers and their application in clinical trials and patient care, directing the Kleberg Center for Molecular Markers, and his visionary T9 program (Ten Thousand Tumors, Ten Thousand Tests, Ten Thousand Therapies) that screens the 40+ most commonly mutationally activated genes, aims at a timely transition from research to clinic.
Arthur D. Lander, M.D., Ph.D., University of California-Irvine – “Control, Constraint and Order in Biology: Examples from Development and Disease”
Professor of Developmental and Cell Biology and Biomedical Engineering at the University of California, Irvine, and Director of the Center for Complex Biological Systems, an NIGMS National Center for Systems Biology . He serves on the editorial boards of PLoS Biology and Journal of Biology, is a member of the American Society for Clinical Investigation, a fellow of the American Association for the Advancement of Science, and a member of the Science Board of the Sante Fe Institute.